Beximco Pharmaceuticals Ltd., one of Bangladesh’s leading pharmaceutical companies, has announced the global launch of Triko, a highly affordable generic version of Trikafta—the breakthrough triple-combination therapy for cystic fibrosis (CF) developed by Vertex Pharmaceuticals (USA).
Cystic fibrosis is a rare, life-threatening genetic disorder that severely limits life expectancy. Worldwide, around 189,000 people are estimated to live with CF, yet only 60% are diagnosed and fewer than 27% receive treatment due to the exorbitant cost of the original therapy.
Against this backdrop, a group of mothers of children with CF launched a community-led global buyers’ club to help patients access Beximco Pharma’s affordable generic version, unveiled as Triko, during the North American Cystic Fibrosis Conference (NACFC) in Seattle, Washington on 23 October 2025.
Triko will be priced at just USD 6,375 per child per year—compared to the U.S. list price of USD 370,000 for the originator brand Trikafta—making it 58 times more affordable. The generic will be available for purchase and supply from Spring 2026, offering renewed hope to thousands of patients who were previously deprived of treatment due to unaffordable costs.
Gayle Pledger, Senior Organizer for Just Treatment and a CF mother from the UK, announced the launch and stated:
“This is a historic moment. Patients, families, and allies have built the solution that the global CF community has been waiting for. We’ve watched children suffer while treatment sat on the shelf, priced out of reach. Today, that changes. We’ve proven that patient power can change what billion-dollar corporations refuse to.”
Triko will cost USD 12,750 per adult per year and USD 6,375 per child per year, providing the same therapeutic value at a fraction of the price. In addition, Beximco Pharma is introducing Bexdeco, a generic version of ivacaftor, one of Triko’s core components, at just USD 5 per tablet.
Mr. Rabbur Reza, Chief Operating Officer of Beximco Pharmaceuticals Ltd., said:
“At Beximco Pharma, our mission is to address unmet medical needs, particularly in areas where access is limited due to high costs. We believe our affordable generic version of Trikafta will have a transformative impact on thousands of cystic fibrosis patients worldwide, helping them lead longer, healthier lives.”
Beximco Pharma developed Triko on humanitarian grounds, following requests from Third World Network (TWN) in Malaysia, along with Just Treatment (UK) and the Right to Breathe global campaign — underscoring its ongoing commitment to accessible healthcare and patient empowerment.
#BeximcoPharma #Triko #CysticFibrosis #AffordableMedicine #HealthcareAccess #TrikaftaGeneric #GlobalHealth #PharmaInnovation #RightToBreathe #JustTreatment #RareDiseaseAwareness #BangladeshPharma